ORASURE TECHNOLOGIES INC
Close on Oct 19, 2026
- Market cap
- $258.18M
- P/E (TTM)
- –
- Dividend yield
- –
About Orasure Technologies
Surgical & Medical Instruments & Apparatus, SIC 3841
OTI, also known as OraSure Technologies, develops, manufactures, and distributes rapid diagnostic testing products and sample management solutions. Its diagnostic line features rapid point-of-care and over-the-counter self-tests for infectious conditions including HIV, Hepatitis C, COVID-19, and sickle cell disease under brand names like OraQuick and InteliSwab. The company also provides sample collection devices and stabilization solutions for genetic and microbiome research. It serves healthcare providers, clinical and academic laboratories, public health agencies, pharmaceutical firms, and retail consumers directly and through commercial partners.
The company operates manufacturing and distribution facilities in Bethlehem, Pennsylvania, while sourcing additional assembly and production services through long-term partner relationships in Canada and Thailand. As of late 2025, the organization employs 500 full-time personnel across its business operations. Products are marketed domestically within the United States as well as internationally across Europe, Canada, and various global markets through internal sales forces and independent distributors.
Summary of the business section of Orasure Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ORASURE TECHNOLOGIES INC
- Headquarters
- Bethlehem, PA
- Address
- 220 E First St 18015
- Phone
- (503) 641-6115
- Website
- oraquick.com
- Employees
- 500, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Philadelphia, PA
Stock & identifiers
- Ticker
- OSUR
- Exchange
- Nasdaq
- IPO date
- Nov 17, 1986
- Shares outstanding
- 69M, Jul 31, 2026
- Public float
- $218.47M, Jun 30, 2025
- Filer category
- Accelerated filer
- Stock splits
- 3-for-1, Apr 8, 1987
- SEC CIK
- 1116463
- CUSIP
- 68554V108
- ISIN
- US68554V1089
- LEI
- 529900GNNJPNM4XHXQ77
- EIN
- 36-4370966
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Manner Carrie Eglinton | President & CEO, Director | 2,190,874 |
| Kenneth J. McGrath | Chief Financial Officer | 589,562 |
| Michele Marie Anthony | SVP Finance & CAO | 185,788 |
| Kathleen Gallagher Weber | Chief Product Officer | 399,518 |
| John P. Kenny | Director | 204,598 |
| Steven Kyle Boyd | Director | 163,234 |
| Robert W. McMahon | Director | 123,137 |
| Lelio Marmora | Director | 148,460 |
| Nancy J. Gagliano | Director | 185,055 |
| John D. Bertrand | Director | 79,767 |
| Mara G. Aspinall | Director | 178,758 |
| David Shulkin | Director | 126,335 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Carrie Eglinton Manner | $4.29M | $671.23K | $1.58M | $23 | $81 |
| FY2024 Carrie Eglinton Manner | $5.60M | -$5.71M | $1.54M | $45 | $85 |
| FY2023 Carrie Eglinton Manner | $6.70M | $13.79M | $1.60M | $102 | $106 |
| FY2022 Carrie Eglinton Manner | $6.75M | $6.65M | $1.46M | $60 | $99 |
| FY2022 Nancy Gagliano M.d. | $940.29K | $347.56K | $1.46M | $60 | $99 |
| FY2022 Stephen S.Tang Ph.d. | $2.77M | $714.65K | $1.46M | $60 | $99 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company had 500 full-time employees, which compares to 501 employees as of December 31, 2024.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 26, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 5, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 19, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 18, 2011 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 11, 2001 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 14, 2000 | Merger | Registration of securities for a merger or exchange offer (S-4) |